Reasonable Timing of Radiotherapy for Stage IV Non-Small-Cell Lung Cancer During Targeted Therapy Based on Tumour Volume Change

Qingsong Li, Na Liang, Xia Zhang, Yi Zhang, Weiwei Ouyang, Shengfa Su, Zhu Ma, Yinxiang Hu, Yichao Geng, Xiaxia Chen, Bing Lu, Qingsong Li, Na Liang, Xia Zhang, Yi Zhang, Weiwei Ouyang, Shengfa Su, Zhu Ma, Yinxiang Hu, Yichao Geng, Xiaxia Chen, Bing Lu

Abstract

Purpose: The aim of this study was to investigate the reasonable timing of radiotherapy for stage IV non-small-cell lung cancer (NSCLC) with EGFR-positive mutations during targeted therapy based on tumour volume change (TVC).

Patients and methods: Simulation Computed Tomography Scan (SCTS) measurements were taken to test TVC in patients with stage IV NSCLC during targeted therapy at intervals of 10 days. The SCTS measurement was terminated when the tumour volume shrinkage rate in the latter simulation compared with the previous simulation was ≤5% or when the time after treatment was 90 days. Then, primary tumour radiotherapy was performed. Related parameters of the radiotherapy plan were compared between the implementation and simulation plans.

Results: Twenty-seven patients were enrolled in the analysis. After treatment, shrinkage of the primary tumour was observed in all patients, but the rate and speed were inconsistent. The average tumour volume decreased obviously within 40 days and was significantly different every 10 days (P ≤ 0.001). The average volume decreased slowly and tended to be stable (P>0.05) after 40 days. After the termination of SCTSs, 21 patients accepted primary tumour radiotherapy. No patients experienced grade 3+ acute radiation toxicity. The implementation radiotherapy plan was significantly better than that before treatment (all P<0.05) but not better than that on the 40th day after treatment (all P>0.05).

Conclusions: To obtain a high radiation dose and control radiation toxicity, the 40th day after targeted therapy may be a reasonable time to start radiotherapy for stage IV NSCLC with EGFR-positive mutations.

Clinical trial registration: https://www.clinicaltrials.gov/ct2/show/NCT03258671, identifier, NCT03258671.

Keywords: non-small-cell lung cancer; radiotherapy; reasonable timing; targeted therapy; tumour volume change.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Li, Liang, Zhang, Zhang, Ouyang, Su, Ma, Hu, Geng, Chen and Lu.

Figures

Figure 1
Figure 1
Changes in the primary tumour volume at different times after targeted therapy in 27 patients.
Figure 2
Figure 2
Regularity of the average value and shrinkage rate for the VP, VN and GTV at different times after targeted therapy in 27 patients.

References

    1. David SE, Douglas EW, Dara LA, Wallace A, Jessica RB, Ankit B, et al. . NCCN Clinical Practice Guidelines in Oncology-Non-Small Cell Lung Cancer. National Comprehensive Cancer Network; (2020). Available at: .
    1. Okamoto I, Mitsudomi T, Nakagawa K, Fukuoka M. The Emerging Role of Epidermal Growth Factor Receptor (EGFR) Inhibitors in First-Line Treatment for Patients With Advanced Non-Small Cell Lung Cancer Positive for EGFR Mutations. Ther Adv Med Oncol (2010) 2(5):301–7. doi: 10.1177/1758834010370698
    1. Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, Engelman JA, et al. . Effect of Crizotinib on Overall Survival in Patients With Advanced Non-Small-Cell Lung Cancer Harbouring ALK Gene Rearrangement: A Retrospective Analysis. Lancet Oncol (2011) 12(11):1004–12. doi: 10.1016/S1470-2045(11)70232-7
    1. Mok TS, W Y-L, A M-J, Garassino MC, Kim HR, Ramalingam SS, et al. . Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med (2017) 376(7):629–40. doi: 10.1056/NEJMoa1612674
    1. Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, Seto T, et al. . Alectinib Versus Crizotinib in Patients With ALK-Positive Non-Small-Cell Lung Cancer (J-ALEX): An Open-Label, Randomised Phase 3 Trial. Lancet (2017) 390(10089):29–39. doi: 10.1016/S0140-6736(17)30565-2
    1. Higginson DS, Chen RC, Tracton G, Morris DE, Halle J, Rosenman JG, et al. . The Impact of Local and Regional Disease Extent on Overall Survival in Patients With Advanced Stage IIIB/IV Non-Small Cell Lung Carcinoma. Int J Radiat Oncol Biol Phys (2012) 84(3):e385–92. doi: 10.1016/j.ijrobp.2012.04.045
    1. Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R, et al. . Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancer. N Engl J Med (2014) 371(21):1963–71. doi: 10.1056/NEJMoa1406766
    1. Su SF, Hu YX, Ouyang WW, Lu B, Ma Z, Li QS, et al. . Overall Survival and Toxicities Regarding Thoracic Three-Dimensional Radiotherapy With Concurrent Chemotherapy for Stage IV Non-Small Cell Lung Cancer: Results of a Prospective Single-Center Study. BMC Cancer (2013) 13(1-9):474. doi: 10.1186/1471-2407-13-474
    1. Gray JE, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. . Three-Year Overall Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-Update From PACIFIC. J Thorac Oncol (2020) 15(2):288–93. doi: 10.1016/j.jtho.2019.10.002
    1. Wang C, Lu X, Lyu Z, Bi N, Wang L. Comparison of Up-Front Radiotherapy and TKI With TKI Alone for NSCLC With Brain Metastases and EGFR Mutation: A Meta-Analysis. Lung Cancer (2018) 122:94–9. doi: 10.1016/j.lungcan.2018.05.014
    1. Lopez Guerra JL, Gomez D, Zhuang Y, Hong DS, Heymach JV, Swisher SG, et al. . Prognostic Impact of Radiation Therapy to the Primary Tumor in Patients With non-Small Cell Lung Cancer and Oligometastasis at Diagnosis. Int J Radiat Oncol Biol Phys (2012) 84(1):e61–7. doi: 10.1016/j.ijrobp.2012.02.054
    1. Patel SH, Rimner A, Foster A, Zhang Z, Woo KM, Yu HA, et al. . Patterns of Initial and Intracranial Failure in Metastatic EGFR-Mutant Non-Small Cell Lung Cancer Treated With Erlotinib. Lung Cancer (2017) 108:109–14. doi: 10.1016/j.lungcan.2017.03.010
    1. Chinnaiyan P, Huang S, Vallabhaneni G, Armstrong E, Varambally S, Tomlins SA, et al. . Mechanisms of Enhanced Radiation Response Following Epidermal Growth Factor Receptor Signaling Inhibition by Erlotinib (Tarceva). Cancer Res (2005) 65(8):3328–35. doi: 10.1158/0008-5472.CAN-04-3547
    1. Das AK, Chen BP, Story MD, Sato M, Minna JD, Chen DJ, et al. . Somatic Mutations in the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor (EGFR) Abrogate EGFR-Mediated Radioprotection in Non-Small Cell Lung Carcinoma. Cancer Res (2007) 67(11):5267–74. doi: 10.1158/0008-5472.CAN-07-0242
    1. Zheng L, Wang Y, Xu Z, Yang Q, Zhu G, Liao XY, et al. . Concurrent EGFR-TKI and Thoracic Radiotherapy as First-Line Treatment for Stage IV Non-Small Cell Lung Cancer Harboring EGFR Active Mutations. Oncologist (2019). doi: 10.1634/theoncologist.2019-0285
    1. Gomez DR, Blumenschein GR, Lee JJ, Hernandez M, Ye R, Camidge DR, et al. . Local Consolidative Therapy Versus Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer Without Progression After First-Line Systemic Therapy: A Multicentre, Randomised, Controlled, Phase 2 Study. Lancet Oncol (2016) 17(12):1672–82. doi: 10.1016/S1470-2045(16)30532-0
    1. Hsu KH, Huang JW, Tseng JS, Chen KW, Weng YC, Yu SL, et al. . Primary Tumor Radiotherapy During EGFR-TKI Disease Control Improves Survival of Treatment Naïve Advanced EGFR-Mutant Lung Adenocarcinoma Patients. Onco Targets Ther (2021) 14:2139–48. doi: 10.2147/OTT.S300267
    1. Zhang Y, Wang W, Xu X, Li Y, Zhang H, Li J, et al. . Impact of Radiotherapy Pattern on the Prognosis of Stage IV Lung Adenocarcinomas Harboring EGFR Mutations. Cancer Manag Res (2021) 13:3293–301. doi: 10.2147/CMAR.S299563
    1. Ma JT, Zheng JH, Han CB, Guo QY. Meta-Analysis Comparing Higher and Lower Dose Radiotherapy for Palliation in Locally Advanced Lung Cancer. Cancer Sci (2014) 105(8):1015–22. doi: 10.1111/cas.12466
    1. Withers HR, Taylor JM, Maciejewski B. The Hazard of Accelerated Tumor Clonogen Repopulation During Radiotherapy. Acta Oncol (1988) 27(2):131–46. doi: 10.3109/02841868809090333
    1. Su S, Li T, Lu B, Wang X, Li J, Chen M, et al. . Three-Dimensional Radiation Therapy to the Primary Tumor With Concurrent Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer: Results of a Multicenter Phase 2 Study From PPRA-RTOG, China. Int J Radiat Oncol Biol Phys (2015) 93(4):769–77. doi: 10.1016/j.ijrobp.2015.08.012
    1. Wang D, Li B, Wang Z, Zhu J, Sun H, Zhang J, et al. . Functional Dose-Volume Histograms for Predicting Radiation Pneumonitis in Locally Advanced Non-Small Cell Lung Cancer Treated With Late-Course Accelerated Hyperfractionated Radiotherapy. Exp Ther Med (2011) 2(5):1017–22. doi: 10.3892/etm.2011.301
    1. Chen M, Chen YY, Bao Y, Xian CG, Liu GZ, Zhang L, et al. . Neoadjuvant Chemotherapy Followed by Late-Course Accelerated Hyperfractionated Radiation Therapy for Locally Advanced Non-Small-Cell Lung Cancer: Long-Term Results of a Phase I/II Clinical Trial. Clin Lung Cancer (2005) 6(5):304–9. doi: 10.3816/CLC.2005.n.010
    1. Ouyang WW, Su SF, Hu YX, Lu B, Ma Z, Li QS, et al. . Radiation Dose and Survival of Patients With Stage IV Non-Small Cell Lung Cancer Undergoing Concurrent Chemotherapy and Thoracic Three-Dimensional Radiotherapy: Reanalysis of the Findings of a Single-Center Prospective Study. BMC Cancer (2014) 14:491(1–8). doi: 10.1186/1471-2407-14-491
    1. Uhlig J, Case MD, Blasberg JD, Boffa DJ, Chiang A, Gettinger SN, et al. . Comparison of Survival Rates After a Combination of Local Treatment and Systemic Therapy vs Systemic Therapy Alone for Treatment of Stage IV Non-Small Cell Lung Cancer. JAMA Netw Open (2019) 2(8):e199702. doi: 10.1001/jamanetworkopen.2019.9702
    1. Koshy M, Malik R, Mahmood U, Rusthoven CG, Sher DJ. Comparative Effectiveness of Aggressive Thoracic Radiation Therapy and Concurrent Chemoradiation Therapy in Metastatic Lung Cancer. Pract Radiat Oncol (2015) 5(6):374–82. doi: 10.1016/j.prro.2015.07.009
    1. Mok TS, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, et al. . Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. J Clin Oncol (2018) 36(22):2244–50. doi: 10.1200/JCO.2018.78.7994
    1. Gomez DR, Tang C, Zhang J, Blumenschein GR, Hernandez M, Lee JJ, et al. . Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. J Clin Oncol (2019) 37(18):1558–65. doi: 10.1200/JCO.19.00201
    1. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. . Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma. N Engl J Med (2009) 361(10):947–57. doi: 10.1056/NEJMoa0810699
    1. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. . Erlotinib Versus Standard Chemotherapy as First-Line Treatment for European Patients With Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer (EURTAC): A Multicentre, Open-Label, Randomised Phase 3 Trial. Lancet Oncol (2012) 13(3):239–46. doi: 10.1016/S1470-2045(11)70393-X
    1. Oya Y, Yoshida T, Kuroda H, Shimizu J, Horio Y, Sakao H, et al. . Association Between EGFR T790M Status and Progression Patterns During Initial EGFR-TKI Treatment in Patients Harboring EGFR Mutation. Clin Lung Cancer (2017) 18(6):698–705.e2. doi: 10.1016/j.cllc.2017.05.004
    1. Park DI, Kim SY, Kim JO, Jung SS, Park HS, Moon JY, et al. . The Prognostic Value of the Tumor Shrinkage Rate for Progression-Free Survival in Patients With Non-Small Cell Lung Cancer Receiving Gefitinib. Tuberc Respir Dis (Seoul) (2015) 78(4):315–20. doi: 10.4046/trd.2015.78.4.315
    1. Tang Y, Xia B, Xie R, Zhang M, Wu K, Wang B, et al. . Timing in Combination With Radiotherapy and Patterns of Disease Progression in Non-Small Cell Lung Cancer Treated With EGFR-TKI. Lung Cancer (2020) 140:65–70. doi: 10.1016/j.lungcan.2019.12.009
    1. Palma DA, Senan S, Tsujino K, Barriger RB, Rengan R, Moreno M, et al. . Predicting Radiation Pneumonitis After Chemoradiation Therapy for Lung Cancer: An International Individual Patient Data Meta-Analysis. Int J Radiat Oncol Biol Phys (2013) 85(2):444–50. doi: 10.1016/j.ijrobp.2012.04.043
    1. Hu YX, Lu B, Zhou HY, Gan JY, Hong W. Changes of Lung Dose Volume and its Clinical Significance in Three-Dimensional Conformal Late Course Accelerated Hyperfractionation Radiotherapy for Non-Small Cell Lung Cancer [J]. Chin J Radiat Oncol (2009) 18(1):57–60. doi: 10.3760/cma.j.issn.1004-4221.2009.01.057
    1. Marks LB, Yorke ED, Jackson A, Ten Haken RK, Constine LS, Eisbruch A, et al. . Use of Normal Tissue Complication Probability Models in the Clinic. Int J Radiat Oncol Biol Phys (2010) 76(3 Suppl):S10–9. doi: 10.1016/j.ijrobp.2009.07.1754
    1. Liang J, Bi N, Wu S, Chen M, Lv C, Zhao L, et al. . Etoposide and Cisplatin Versus Paclitaxel and Carboplatin With Concurrent Thoracic Radiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: A Multicenter Randomized Phase III Trial. Ann Oncol (2017) 28(4):777–83. doi: 10.1093/annonc/mdx009

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir